Biophan Technologies CEO Michael Weiner to Address Atlantic Nano Forum.

ROCHESTER, N.Y. -- CEO Michael Weiner To Discuss Company's Next-Generation R&D in Nanotechnology for Biomedical Applications and Products

Biophan Technologies, Inc. (OTC BB: BIPH), a developer of next-generation biomedical technology, will be a featured presenter Tuesday September 28th at the upcoming Atlantic Nano Forum, a leading industry education group designed to advance innovation and development in the nanotechnology field. Biophan CEO Michael Weiner will present an overview of the Company's portfolio of intellectual property and products in biomedical applications of nanotechnology.

The Atlantic Nano Forum has emerged as an important avenue of education for the nanotechnology community and venture capitalists, as well as members of the U.S. Patent and Trademark Office (PTO), whose patent examiners must remain at the forefront of the field. The Forum invites the most important leaders in academia and industry to present lectures at its monthly meetings.

"Everyone who participates in leading-edge research and markets, such as nanotechnology, has a duty to the scientific community to help advance and broaden understanding of the field," said Mr. Weiner. "Biophan is glad to be a part of this educational process, and we always look forward to meeting with our colleagues in industry and government to talk about our exciting work in biomedical innovation, and to learn what others are doing."

About Atlantic Nano Forum

The Atlantic Nano Forum's mission is to advance innovation through assistance to the nanotechnology community and the U.S. Patent and Trademark Office (PTO). By providing detailed, technology-based lectures in specified areas at no cost to the PTO, technical information and resources are shared to sharpen skills of the examiners and improve perception that the PTO is sufficiently trained to handle the fast emerging areas of nanotechnology. The Atlantic Nano Forum

holds monthly technology seminars (except December), which are open to the public, in Northern Virginia, at a location convenient to the PTO, Ronald Reagan National Airport and Dulles International Airport. For more information on Atlantic Nano Forum, visit www.atlanticnanoforum.org.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with magnetic resonance imaging (MRI) equipment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create enhanced MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan product lines include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors have 19 issued U.S. patents and 61 patents pending, in areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE: BSX) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.